Which injection fits which situation

Most of the time, the practical split is straightforward: cortisone is the more predictable option when the main problem is a painful flare, a need for quicker relief over the next few weeks, or symptom control that is expected to help for roughly 3 months rather than long term. It can also still have a role when a radiologically guided hip injection is being used to help clarify whether the joint itself is the pain source. PRP is a different conversation. It is usually considered in earlier or mild-to-moderate hip osteoarthritis, when the aim is symptom improvement over time rather than fast relief and some uncertainty is acceptable.

PRP also sits further from routine care. AAHKS says most surgeons and medical societies have not recommended it as standard osteoarthritis treatment, and NYU describes PRP hip injections as experimental for this use. That does not mean it never helps; it means expectations need to stay measured because the hip evidence is mixed and protocols vary. Neither PRP nor cortisone should be presented as cartilage regrowth, and neither is a convincing fix for advanced, bone-on-bone arthritis. The real choice usually comes down to four points: speed, stage of arthritis, tolerance for uncertainty, and the recovery plan after injection.

When cortisone still makes sense

In hip osteoarthritis, cortisone’s strongest case is timing, not permanence. A 2024 network meta-analysis of 16 randomised trials found steroid injections improved pain and function at 3 months versus placebo, and a review of hip studies reported benefit lasting up to about 12 weeks, with no clear advantage by 6 months. That pattern fits an acute flare, a short period when pain is disrupting sleep, travel or physiotherapy, or a situation where clinicians need to help distinguish pain coming from the hip joint from pain referred from elsewhere.

The caution comes with repetition. Faster relief does not make cortisone a durable management plan, and the published safety picture is still being worked out. A 2017 JAMA knee osteoarthritis trial of repeated triamcinolone is often cited as a warning signal because it reported greater cartilage-volume loss than saline; importantly, that was a knee study and not a hip efficacy trial. Observational concerns summarised by Harvard in 2019 included accelerated osteoarthritis in about 7% to 8% and unusual fracture or osteonecrosis in about 1% each, while a 2022 RSNA series found severe complications in 1% overall. Taken together, cortisone still has a legitimate role in carefully selected cases as a short-term bridge, rather than a rolling strategy for ongoing hip OA.

Who may be a PRP candidate

Stage matters more than enthusiasm for PRP. In the hip, the more plausible candidates are usually those with earlier disease rather than marked joint-space loss or major structural change. That fits the published study populations: hip PRP trials commonly enrol grade 2–3 osteoarthritis, and a 2022 study reported stronger response signals in lower-grade disease such as Tönnis 1–2 than in more advanced hips. In practical terms, PRP is more often discussed when symptoms are persistent enough to push beyond simple painkillers, but the joint is not yet so damaged that any injection is unlikely to change much.

Goals and expectations matter just as much. A person hoping for gradual symptom improvement over months may be a better fit than someone who needs fast, predictable relief for the next few weeks. Because PRP still sits outside routine hip OA care in positions from AAHKS and centres such as NYU, it is usually a discussion for patients who accept uncertainty rather than those looking for the most established injection pathway.

Practical fit also counts. PRP protocols vary between clinics, and typical academic guidance asks patients to avoid NSAIDs and strenuous exercise for about 2 weeks after treatment. That tends to suit people who can work around a short recovery plan and possible out-of-pocket cost. If the pain pattern also includes lumbar symptoms, adductor or groin tendon pain, labral-type clicking, or marked mechanical catching, the diagnosis often needs another look before PRP moves up the list.

What the PRP evidence actually shows

The hip PRP data are best read as promising but conflicted. A 2024 systematic review that pooled 5 randomised trials reported pain and function improvement after PRP, and a 2022 trial in grade 2–3 hip osteoarthritis found that PRP-based treatment produced better 6-month WOMAC and Lequesne scores than hyaluronic acid alone. Those findings suggest PRP may help some patients, particularly in certain head-to-head comparisons, but they do not settle the bigger question of whether PRP has a reliable effect in hip OA itself.

The reason the evidence remains unsettled is that a 2024 double-blind placebo-controlled trial in Kellgren-Lawrence grade 2/3 hips found no meaningful difference between PRP and saline across 6 months for pain, function or quality of life. That is an important result, because saline-controlled trials test whether improvement goes beyond the effect of the injection procedure and the condition’s normal fluctuation. In other words, PRP cannot honestly be described as proven for hip osteoarthritis on the current direct evidence.

Safety is not the main sticking point in the short term. Across the 5-trial systematic review, no major adverse events were reported, and the side effects described were generally transient and minor. The harder problem is inconsistency: PRP preparations differ, leukocyte content is not standardised, injection schedules vary, and the best protocol for the hip is still unclear. Taken together, PRP remains a reasonable discussion point for selected hip OA cases, but as an evidence-mixed option rather than a standard recommendation.

What recovery and timing usually look like

From a practical recovery point of view, the useful anchors are the first few days, the first fortnight and the 3-month mark. Cortisone is usually the lower-friction option after the injection itself: activity is commonly pared back briefly rather than for weeks, and any benefit is generally expected on a short timetable because its main role is temporary symptom control. In the hip OA literature, that short-term window is where the evidence is strongest, with benefit supported through roughly 12 weeks or 3 months rather than at 6 months. Some patients also report a brief post-injection flare before the joint settles.

PRP tends to ask more of the first 2 weeks. Academic post-procedure guidance commonly advises avoiding strenuous exercise at the treated site for about 2 weeks, and some centres also advise avoiding NSAIDs for about 2 weeks. Short-lived soreness can happen in the first day or two, and if PRP helps, the change is usually judged over several weeks rather than over the first 48 hours. That makes it a poor fit when relief is needed for a near-term event. There is no single universal PRP script, because preparation methods and dosing schedules vary between clinics. For both injections, the realistic aim is symptom control and support of the joint environment, not cartilage being rebuilt on demand.

How to decide at consultation

The most useful consultation question is not simply “PRP or cortisone?”, but what problem needs solving over the next 3 to 6 months. A sensible discussion starts with four anchors: how advanced the hip osteoarthritis looks on current X-rays or MRI, how much walking, sleep or stairs are limited now, what has already been tried, and whether the aim is fast temporary relief, to test whether the joint itself is driving the pain, or to try a biologic option despite uncertainty.

In practical terms, cortisone usually fits the first two goals. Its position is more mainstream, although not completely uniform: the 2019 ACR/Arthritis Foundation guideline strongly recommended intra-articular glucocorticoid injections for hip OA, whereas the 2019 OARSI guideline did not recommend hip corticosteroid injections. That said, the direct trial evidence for steroid is still more settled than for PRP, with a 2024 network meta-analysis finding benefit at 3 months but not at 6. PRP sits further from standard care; AAHKS describes it as non-routine for osteoarthritis, and hip studies remain mixed.

A plain-language rule follows from that. Cortisone is generally the better fit when speed or diagnostic clarity matters. PRP may still be discussed in selected hips that look more like the grade 2–3 trial populations than end-stage arthritis, provided the patient accepts less certain and less standardised evidence. When symptoms and imaging do not match well, or the joint already looks advanced, the more useful next step may be a broader joint-preservation or surgical opinion rather than another injection. Where that choice is not straightforward, specialist assessment at London Cartilage Clinic on Harley Street can help determine whether any injection is sensible at all; consultations can be arranged via londoncartilage.com.

1. [1] Efficacy and safety of platelet-rich plasma (PRP) intra-articular injections in hip osteoarthritis: A systematic review of randomized clinical trials. (2024). https://doi.org/10.7759/cureus.72057 https://doi.org/10.7759/cureus.72057
2. [2] Comparison between the effects of ultrasound guided intra-articular injections of platelet-rich plasma (PRP), high molecular weight hyaluronic acid, and their combination in hip osteoarthritis: A randomized clinical trial. (2022). https://doi.org/10.1186/s12891-022-05787-8 https://doi.org/10.1186/s12891-022-05787-8
3. [3] Effect of platelet-rich plasma injections versus placebo on pain and quality of life in patients with hip osteoarthritis: A double-blind, randomized clinical trial. (2024). https://doi.org/10.5606/tftrd.2024.13855 https://doi.org/10.5606/tftrd.2024.13855
4. [4] Umbilical cord PRP vs. autologous PRP for the treatment of hip osteoarthritis. (2022). https://doi.org/10.3390/jcm11154505 https://doi.org/10.3390/jcm11154505
5. [5] Clinical efficacy of multiple intra-articular injection for hip osteoarthritis. (2024). https://doi.org/10.1302/0301-620X.106B6.BJJ-2023-1272.R1 https://doi.org/10.1302/0301-620X.106B6.BJJ-2023-1272.R1